Drug-resistant epilepsy (DRE) affects many children. Vagus nerve stimulation (VNS) may improve seizure control; however, its role in children with genetic etiologies of epilepsy is not well described. The authors systematically reviewed the literature to examine the effectiveness of VNS in this cohort.
In January 2021, the authors performed a systematic review of the PubMed/MEDLINE, SCOPUS/Embase, Cochrane, and Web of Science databases to investigate the impact of VNS on seizure outcomes in children with genetic etiologies of epilepsy. Primary outcomes included seizure freedom rate, ≥ 90% seizure reduction rate, and ≥ 50% seizure reduction rate. Secondary outcomes were seizure severity and quality of life (QOL), including cognitive, functional, and behavioral outcomes. A random-effects meta-analysis was performed.
The authors identified 125 articles, of which 47 with 216 nonduplicate patients were analyzed. Common diagnoses were Dravet syndrome (DS) (92/216 patients [42.6%]) and tuberous sclerosis complex (TSC) (63/216 [29.2%]). Seizure freedom was not reported in any patient with DS; the pooled proportion (95% CI) of patients with ≥ 50% seizure reduction was 41% (21%–58%). Secondary cognitive outcomes of VNS were variable in DS patients, but these patients demonstrated benefits in seizure duration and status epilepticus. In TSC patients, the pooled (95% CI) seizure freedom rate was 40% (12%–71%), ≥ 90% seizure reduction rate was 31% (8%–56%), and ≥ 50% reduction rate was 68% (48%–91%). Regarding the secondary outcomes of VNS in TSC patients, several studies reported decreased seizure severity and improved QOL outcomes. There was limited evidence regarding the use of VNS to treat patients with other genetic etiologies of epilepsy, such as mitochondrial disease, Rett syndrome, Doose syndrome, Landau-Kleffner syndrome, Aicardi syndrome, Angelman syndrome, ring chromosome 20 syndrome, and lissencephaly; variable responses were reported in a limited number of cases.
The authors conducted a systematic review of VNS outcomes in children with genetic etiologies of DRE. Among the most studied conditions, patients with TSC had substantial seizure reduction and improvements in QOL, whereas those with DS had less robust seizure reduction. Increased testing, diagnosis, and long-term follow-up studies are necessary to better characterize VNS response in these children.
INCLUDE WHEN CITING Published online March 18, 2022; DOI: 10.3171/2022.1.PEDS222.
Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069–1077.
Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179–2193.
Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav. 2018;88S:2–10.
Stevelink R, Sanders MW, Tuinman MP, et al. Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review. Epileptic Disord. 2018;20(2):99–115.
Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68(6):1327–1332.
Zamponi N, Passamonti C, Cappanera S, Petrelli C. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8–14.
Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52(11):988–993.
Wilfong AA, Schultz RJ. Vagus nerve stimulation for treatment of epilepsy in Rett syndrome. Dev Med Child Neurol. 2006;48(8):683–686.
Arthur TM, Saneto RP, de Menezes MS, et al. Vagus nerve stimulation in children with mitochondrial electron transport chain deficiencies. Mitochondrion. 2007;7(4):279–283.
Zhang K, Hu WH, Zhang C, Meng FG, Chen N, Zhang JG. Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis. Epilepsy Res. 2013;105(3):377–383.
Prideaux L, Barton S, Maixner W, Harvey AS. Potential delays in referral and assessment for epilepsy surgery in children with drug-resistant, early-onset epilepsy. Epilepsy Res. 2018;143:20–26.
Yalnizoglu D, Ardicli D, Bilginer B, et al. Long-term effects of vagus nerve stimulation in refractory pediatric epilepsy: a single-center experience. Epilepsy Behav. 2020;110:107147.
Morris GL III, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(16):1453–1459.
Food and Drug Administration. PMA P970003/S207: FDA Summary of Safety and Effectiveness Data June 23, 2017. Accessed February 9, 2022. https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s207b.pdf
Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children. Epilepsia. 2014;55(10):1576–1584.
Lagae L, Verstrepen A, Nada A, et al. Vagus nerve stimulation in children with drug-resistant epilepsy: age at implantation and shorter duration of epilepsy as predictors of better efficacy?. Epileptic Disord. 2015;17(3):308–314.
Elliott RE, Rodgers SD, Bassani L, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr. 2011;7(5):491–500.
Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg. 2011;115(6):1248–1255.
Englot DJ, Rolston JD, Wright CW, Hassnain KH, Chang EF. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery. 2016;79(3):345–353.
Klinkenberg S, van den Bosch CN, Majoie HJ, et al. Behavioural and cognitive effects during vagus nerve stimulation in children with intractable epilepsy—a randomized controlled trial. Eur J Paediatr Neurol. 2013;17(1):82–90.
Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav. 2008;13(2):357–360.
Elliott RE, Carlson C, Kalhorn SP, et al. Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery. Epilepsy Behav. 2009;16(3):454–460.
Zamponi N, Petrelli C, Passamonti C, Moavero R, Curatolo P. Vagus nerve stimulation for refractory epilepsy in tuberous sclerosis. Pediatr Neurol. 2010;43(1):29–34.
Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-Experimental Designs for Generalized Causal Inference. Houghton Mifflin Company;2002.
Fulton SP, Van Poppel K, McGregor AL, Mudigoudar B, Wheless JW. Vagus nerve stimulation in intractable epilepsy associated with SCN1A gene abnormalities. J Child Neurol. 2017;32(5):494–498.
Sirsi D, Khan M, Arnold ST. Vagal nerve stimulation: is it effective in children with Dravet syndrome?. J Pediatr Epilepsy. 2016;5(1):7–10.
Chen CY, Lee HT, Chen CC, et al. Short-term results of vagus nerve stimulation in pediatric patients with refractory epilepsy. Pediatr Neonatol. 2012;53(3):184–187.
Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure. 2009;18(1):34–37.
Bremer A, Lossius MI, Nakken KO. Dravet syndrome—considerable delay in making the diagnosis. Acta Neurol Scand. 2012;125(5):359–362.
Caraballo RH. Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet. Epilepsia. 2011;52(suppl 2):79–82.
Cersósimo RO, Bartuluchi M, Fortini S, Soraru A, Pomata H, Caraballo RH. Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord. 2011;13(4):382–388.
Dlouhy BJ, Miller B, Jeong A, Bertrand ME, Limbrick DD Jr, Smyth MD. Palliative epilepsy surgery in Dravet syndrome-case series and review of the literature. Childs Nerv Syst. 2016;32(9):1703–1708.
Lund C, Kostov H, Blomskjøld B, Nakken KO. Efficacy and tolerability of long-term treatment with vagus nerve stimulation in adolescents and adults with refractory epilepsy and learning disabilities. Seizure. 2011;20(1):34–37.
Majoie HJ, Berfelo MW, Aldenkamp AP, Renier WO, Kessels AG. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure. 2005;14(1):10–18.
Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for refractory epilepsy in children: more to VNS than seizure frequency reduction. Epilepsia. 2009;50(5):1220–1228.
Alexopoulos AV, Kotagal P, Loddenkemper T, Hammel J, Bingaman WE. Long-term results with vagus nerve stimulation in children with pharmacoresistant epilepsy. Seizure. 2006;15(7):491–503.
Benifla M, Rutka JT, Logan W, Donner EJ. Vagal nerve stimulation for refractory epilepsy in children: indications and experience at The Hospital for Sick Children. Childs Nerv Syst. 2006;22(8):1018–1026.
Danielsson S, Viggedal G, Gillberg C, Olsson I. Lack of effects of vagus nerve stimulation on drug-resistant epilepsy in eight pediatric patients with autism spectrum disorders: a prospective 2-year follow-up study. Epilepsy Behav. 2008;12(2):298–304.
Hosain S, Nikalov B, Harden C, Li M, Fraser R, Labar D. Vagus nerve stimulation treatment for Lennox-Gastaut syndrome. J Child Neurol. 2000;15(8):509–512.
Kang HC, Hwang YS, Kim DS, Kim HD. Vagus nerve stimulation in pediatric intractable epilepsy: a Korean bicentric study. Acta Neurochir Suppl (Wien). 2006;99:93-96.
Mikati MA, Ataya NF, El-Ferezli JC, et al. Quality of life after vagal nerve stimulator insertion. Epileptic Disord. 2009;11(1):67–74.
Nagarajan L, Walsh P, Gregory P, Lee M. VNS therapy in clinical practice in children with refractory ep0ilepsy. Acta Neurol Scand. 2002;105(1):13–17.
Overwater IE, Bindels-de Heus K, Rietman AB, et al. Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs. Epilepsia. 2015;56(8):1239–1245.
Parain D, Penniello MJ, Berquen P, Delangre T, Billard C, Murphy JV. Vagal nerve stimulation in tuberous sclerosis complex patients. Pediatr Neurol. 2001;25(3):213–216.
Zamponi N, Rychlicki F, Cardinali C, Luchetti A, Trignani R, Ducati A. Intermittent vagal nerve stimulation in paediatric patients: 1-year follow-up. Childs Nerv Syst. 2002;18(1-2):61–66.
Zamponi N, Rychlicki F, Corpaci L, Cesaroni E, Trignani R. Vagus nerve stimulation (VNS) is effective in treating catastrophic 1 epilepsy in very young children. Neurosurg Rev. 2008;31(3):291–297.
Zamponi N, Passamonti C, Cesaroni E, Trignani R, Rychlicki F. Effectiveness of vagal nerve stimulation (VNS) in patients with drop-attacks and different epileptic syndromes. Seizure. 2011;20(6):468–474.
Fujimoto A, Yamazoe T, Yokota T, et al. Clinical utility of vagus nerve stimulation for progressive myoclonic epilepsy. Seizure. 2012;21(10):810–812.
Blount JP, Tubbs RS, Kankirawatana P, et al. Vagus nerve stimulation in children less than 5 years old. Childs Nerv Syst. 2006;22(9):1167–1169.
Nolan DA, Chen B, Michon AM, Salatka E, Arndt D. A Rasmussen encephalitis, autoimmune encephalitis, and mitochondrial disease mimicker: expanding the DNM1L-associated intractable epilepsy and encephalopathy phenotype. Epileptic Disord. 2019;21(1):112–116.
Hornig GW, Murphy JV, Schallert G, Tilton C. Left vagus nerve stimulation in children with refractory epilepsy: an update. South Med J. 1997;90(5):484–488.
Kanai S, Okanishi T, Nishimura M, et al. Successful corpus callosotomy for Doose syndrome. Brain Dev. 2017;39(10):882–885.
Fan PC, Peng SS, Yen RF, Shieh JY, Kuo MF. Neuroimaging and electroencephalographic changes after vagus nerve stimulation in a boy with medically intractable myoclonic astatic epilepsy. J Formos Med Assoc. 2014;113(4):258–263.
Parker AP, Polkey CE, Binnie CD, Madigan C, Ferrie CD, Robinson RO. Vagal nerve stimulation in epileptic encephalopathies. Pediatrics. 1999;103(4 Pt 1):778–782.
Kokoszka MA, McGoldrick PE, La Vega-Talbott M, et al. Epilepsy surgery in patients with autism. J Neurosurg Pediatr. 2017;19(2):196–207.
Bollo RJ, Kalhorn SP, Carlson C, Haegeli V, Devinsky O, Weiner HL. Epilepsy surgery and tuberous sclerosis complex: special considerations. Neurosurg Focus. 2008;25(3):E13.
Englot DJ, Rolston JD, Wang DD, Hassnain KH, Gordon CM, Chang EF. Efficacy of vagus nerve stimulation in posttraumatic versus nontraumatic epilepsy. J Neurosurg. 2012;117(5):970–977.
Neese SL, Sherill LK, Tan AA, et al. Vagus nerve stimulation may protect GABAergic neurons following traumatic brain injury in rats: an immunocytochemical study. Brain Res. 2007;1128(1):157–163.
Mühlebner A, van Scheppingen J, de Neef A, et al. Myelin pathology beyond white matter in tuberous sclerosis complex (TSC) cortical tubers. J Neuropathol Exp Neurol. 2020;79(10):1054–1064.
Pan I, LoPresti MA, Clarke DF, Lam S. The effectiveness of medical and surgical treatment for children with refractory epilepsy. Neurosurgery. 2020;88(1):E73–E82.
Boon P, D’Havé M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia. 2002;43(1):96–102.
Ben-Menachem E, Hellström K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology. 2002;59(6)(suppl 4):S44–S47.
Bernstein AL, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav. 2007;10(1):134–137.
Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex. Epilepsy Behav. 2016;63:79–88.
McLachlan RS, Sadler M, Pillay N, et al. Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor?. Eur Neurol. 2003;50(1):16–19.
Weber YG, Biskup S, Helbig KL, Von Spiczak S, Lerche H. The role of genetic testing in epilepsy diagnosis and management. Expert Rev Mol Diagn. 2017;17(8):739–750.
Hebbar M, Mefford HC. Recent advances in epilepsy genomics and genetic testing. F1000Res. 2020;9
Park YD. The effects of vagus nerve stimulation therapy on patients with intractable seizures and either Landau-Kleffner syndrome or autism. Epilepsy Behav. 2003;4(3):286–290.
Kasasbeh AS, Gurnett CA, Smyth MD. Palliative epilepsy surgery in Aicardi syndrome: a case series and review of literature. Childs Nerv Syst. 2014;30(3):497–503.
Tomei KL, Mau CY, Ghali M, Pak J, Goldstein IM. Vagal nerve stimulation for medically refractory epilepsy in Angelman syndrome: a series of three cases. Childs Nerv Syst. 2018;34(3):395–400.
Alpman A, Serdaroglu G, Cogulu O, Tekgul H, Gokben S, Ozkinay F. Ring chromosome 20 syndrome with intractable epilepsy. Dev Med Child Neurol. 2005;47(5):343–346.
Chawla J, Sucholeiki R, Jones C, Silver K. Intractable epilepsy with ring chromosome 20 syndrome treated with vagal nerve stimulation: case report and review of the literature. J Child Neurol. 2002;17(10):778–780.
Herrgård E, Mononen T, Mervaala E, et al. More severe epilepsy and cognitive impairment in the offspring of a mother with mosaicism for the ring 20 chromosome. Epilepsy Res. 2007;73(1):122–128.
Baba S, Sugawara Y, Moriyama K, et al. Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation. Brain Dev. 2017;39(4):341–344.
Fernandez L, Gedela S, Tamber M, Sogawa Y. Vagus nerve stimulation in children less than 3 years with medically intractable epilepsy. Epilepsy Res. 2015;112:37–42.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 989 | 989 | 275 |
Full Text Views | 93 | 93 | 16 |
PDF Downloads | 121 | 121 | 22 |
EPUB Downloads | 0 | 0 | 0 |